A study of CDK4/6 inhibitor drugs for medulloblastoma, a brain tumor in children
Official title: Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study looks for gene changes that show which medulloblastoma tumors these drugs might work on.
Read our full plain-language summary
What the trial team says
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
Key facts
- Registry number
- NCT06959979
- Stage of testing
- Early phase 1
- Conditions studied
- Medulloblastoma, Childhood
Where it is running
This trial lists 1 site.
-
ROMA
- Fondazione Policlinico Gemelli Irccs (Roma)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.